Latest HVIVO Press Release: 11.04.19 Preliminary Results 2018
hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.
hVIVO brings a broad range of capabilities and know how gained from delivering drug discovery and development testing services in respiratory diseases for over 20 years. Our services include a range of challenge studies, disease models, and other analytical services for early phase clinical development in respiratory diseases such as influenza, HRV, RSV and asthma.
hVIVO's shares are listed on the AIM market of the London Stock Exchange under the HVO ticker. This area contains investment and shareholder information.
A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.